Holen Sie sich die Stockscreener-App
1.48
0.00%
0.00
Handel nachbörslich:
1.48
Schlusskurs vom Vortag:
$1.48
Offen:
$1.48
24-Stunden-Volumen:
46,186
Relative Volume:
3.83
Marktkapitalisierung:
$80.73M
Einnahmen:
$118.18M
Nettoeinkommen (Verlust:
$5.99M
KGV:
11.22
EPS:
0.1319
Netto-Cashflow:
$-12.91M
1W Leistung:
+0.00%
1M Leistung:
-6.92%
6M Leistung:
-6.33%
1J Leistung:
-27.80%
1-Tages-Spanne:
$1.46
$1.53
1-Wochen-Bereich:
$1.43
$1.53
52-Wochen-Spanne:
$1.17
$2.62
Intercure Ltd Stock (INCR) Company Profile
Vergleichen Sie INCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCR
Intercure Ltd
|
1.48 | 80.73M | 118.18M | 5.99M | -12.91M | 0.1319 |
|
RGC
Regencell Bioscience Holdings Ltd
|
10.36 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.08 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.26 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.05 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Intercure Ltd Stock (INCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-05-18 | Hochstufung | Canaccord Genuity | Speculative Buy → Buy |
Intercure Ltd Aktie (INCR) Neueste Nachrichten
InterCure (NASDAQ:INCR) Stock Price Up 1.9% – What’s Next? - Defense World
InterCure And Cookies Successfully Launch Flagship Pharmacy In Be'er Sheva, Israel - Barchart.com
InterCure (NASDAQ:INCR) Shares Down 4.4% – What’s Next? - Defense World
InterCure Reports FY2024 Results - mg Magazine
InterCure Reports Strong Start to 2025 Amid Recovery Efforts - TipRanks
InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025 - PR Newswire
Intercure Ltd. Delays Yearly Report Filing - TipRanks
InterCure Bounces Back: 25% Q1 Growth Expected as Cannabis Giant Expands to Germany Despite War Challenges - Stock Titan
Interbusiness, Virdis partner to distribute Intercure products - Rubber News
InterCure (NASDAQ:INCR) Stock Price Down 3.4% – Time to Sell? - Defense World
InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak - GuruFocus.com
InterCure (NASDAQ:INCR) Shares Down 0.7%What's Next? - MarketBeat
InterCure Announces Leadership Change and Secures $18.2 Million Financing - TipRanks
Short Interest in InterCure Ltd. (NASDAQ:INCR) Expands By 96.2% - MarketBeat
Jane Street Group LLC Acquires New Stake in InterCure Ltd. (NASDAQ:INCR) - Defense World
InterCure (NASDAQ:INCR) Trading Up 3.7% – Should You Buy? - Defense World
Cannabis co InterCure raising NIS 66m for Nir Oz facilityGlobes - Globes - Israel Business News
InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility - PR Newswire
Synbiotic's CAGR Forecast at 80%, ECS Botanics to Expand Footprint in Germany, & More from Intercure - Business of Cannabis -
Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company - Benzinga
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Market Exclusive
InterCure nears break even in first half of 2024, despite ongoing Israel-Hamas war - Crain's Chicago Business
InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million - GlobeNewswire
InterCure Announces Expansion of its Strategic partnership with Cookies to Germany - Business Wire
IM Cannabis Merger Scrapped, Cel AI Gets a New CEO, & More from Intercure - Business of Cannabis
Analyst: Israel’s InterCure paving path to big gains - Green Market Report
InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference - Business Wire
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million - Business Wire
InterCure: Bargain Israel Cannabis Play (NASDAQ:INCR) - Seeking Alpha
InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint - Business Wire
InterCure Provides Update Regarding Nir Oz Facility in Israel - Cannabis Business Times
InterCure Provides an Update Regarding Nir Oz Facility - GlobeNewswire
InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain - GlobeNewswire
InterCure Wins Cannolam Arbitration Proceeding - GlobeNewswire
InterCure Ltd Issues Update Regarding the Security Situation in Israel By Investing.com - Investing.com UK
Israeli Cannabis Adjusts to War - Green Market Report
InterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY - GlobeNewswire
InterCure Ltd. Announces Proposed Voluntary Delisting from - GlobeNewswire
Cookies launches flagship store in Austria with InterCure - Business of Cannabis
Intercure Counter-Sued By Better, Cantourage Sees Stock Jump 30%, & Tikun Olam Cannbit To Be Acquired - Business of Cannabis
InterCure Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its Subsidiary - Stock Titan
InterCure to distribute Mike Tyson’s cannabis internationally - Mugglehead Magazine
InterCure Ltd. Partners with TYSON 2.0 in Israel, Australia, United Kingdom, Germany and Other EU Countries - GlobeNewswire
InterCure Delivers Rising Revenue, Positive Cash Flow - Green Market Report
InterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results - GlobeNewswire
InterCure Files Lawsuit Against Cann Pharmaceuticals to Recover Funds Following Failed Merger - GlobeNewswire
InterCure Announces the Termination of its Acquisition Agreement with Cann Pharmaceutical (dba Better) - GlobeNewswire
InterCure: Why The Company Is Grossly Undervalued By Wall Street - Seeking Alpha
InterCure Announces Exclusive International Partnership Agreement with Award Winning Cannabis Brand "Binske" - GlobeNewswire
Finanzdaten der Intercure Ltd-Aktie (INCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.01%
0.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):